and endoscopic response at several possible eosinophil count cutpoints (eos/hpf). Predictors of response were also assessed. RESULTS: Of 224 treatments in 199 patients, 76% were associated with symptomatic improvement, 68% with endoscopic improvement, and 60% with both. Of treatments that resulted in a post-treatment count of <15 eos/hpf, 90% were associated with an endoscopic response, 88% with a symptomatic response, and 81% with both symptomatic and endoscopic responses. Using a <15 eos/hpf threshold, the area under the curves (AUCs) were 0.70, 0.78, and 0.75 for symptomatic, endoscopic, and symptomatic/endoscopic responses, respectively. Lower histologic cut-points did not result in a substantial gain in response, but decreased the AUC. CONCLUSION: In this large cohort of EoE patients, rates of symptomatic and endoscopic improvement were generally associated with histologic improvement. A histologic cutoff for treatment response of <15 eos/hpf may balance clinical outcomes and test performance.
Journal of
Gastroenterology and Hepatology Researchendoscopist-reported assessment of improvement [yes/no]), and both symptom and endoscopic response.
Data AnalysisAll data were analyzed using SAS version 9.3 (Cary, NC). Bivariate analyses were performed with chi-square testing for categorical variables. Because all continuous variables were not normally distributed, the Wilcoxon two-tailed t approximation (rank-sum) was used. For evaluation of treatment outcomes, a per-treatment analysis was performed, allowing inclusion of both outcomes for patients who underwent separate courses of steroid and dietary therapy. Receiver operator characteristic (ROC) curves were generated and the area under the curve (AUC) was calculated for multiple values of the post-treatment eosinophil count (eos/hpf) as well as for the percentage change in the eosinophil count compared to baseline. Because dilation can produce symptomatic improvement without endoscopic or histologic improvement, we conducted a subgroup analysis among patients not undergoing dilation at baseline (prior to treatment) to evaluate outcomes. For patients treated with tCS, those with concordant symptomatic, endoscopic, and histologic response (<15 eos/hpf) were compared to those without using a bivariate analysis. For inclusion in this portion of the analysis, patients had to have recorded symptomatic and endoscopic response variables and pre-and post-treatment eosinophil counts. A logistic regression model was constructed to assess predictors of concordant response by including all variables significant at the p<0.2 level and then reducing until all factors were significant at the p<0.05 level. This study was approved by the UNC Institutional Review Board.
RESULTSWe identified 199 patients with EoE meeting inclusion criteria. The mean age was 27, and they were predominately white (84%), male (68%), and had a history of atopic disease (52%) ( Table 1). Eightythree percent were adults (≥18 years old) at the time of diagnosis. The predominant baseline symptom was dysp...